Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder

Thase, Michael E.; Chen, Dalei; Edwards, J.B.; Ruth, Adam

doi:10.1097/yic.0000000000000045

Cited by 41 publications

(31 citation statements)

References 26 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While this showed an antidepressant effect when microinjected into the septum, no such effect was seen in the raphe of male rats [74]. This indicates that stimulation of the postsynaptic 5-HT 1A receptors is responsible for establishing the antidepressant effect caused by 5-HT 1A -R agonists when managed through a systemic pathway, since stimulation of the 5-HT 1A somatodendritic auto-receptors in the raphe inhibits the release of 5-HT and the electrical activity of the raphe [75].…”

Section: Serotonin -A Chemical Messenger Between All Types Of Living mentioning

confidence: 91%

“…In recent years, administration of vilazodone has shown antidepressant [75,76] and anxiolytic effects by eliminating physical and somatic symptoms in women with generalized anxiety disorder, after 8 weeks of treatment at daily doses of 20-40 mg [77,78]. This effect is due to the action mechanism of this SSRI, which is a partial agonist of postsynaptic 5-HT 1A receptors.…”

Section: Serotonin -A Chemical Messenger Between All Types Of Living mentioning

confidence: 99%

See 1 more Smart Citation

Association of 5-HT1A Receptors with Affective Disorders

Soria-Fregozo¹,

Vega²,

FranciscoRodríguez-Landa³

et al. 2017

Serotonin - A Chemical Messenger Between All Types of Living Cells

View full text Add to dashboard Cite

Serotonin or 5-hydroxytryptamine (5-HT) is synthesized in both the brain and peripheral system, which exert their actions at a wide family of receptors classified as 5-HT 1 to 5-HT 7 . Pharmacological, behavioral, and clinical studies involve particularly to the 5-HT 1A receptors (5-HT 1A -R) -auto-receptors (presynaptic) and heteroreceptors (postsynaptic) -in the control of motivated behavior, and consequently in the physiopathology of affective disorders and in the action mechanism of antidepressant drugs. In this way, some research support that 5-HT 1A -R participates in the delayed effect of different types of antidepressants, including selective serotonin reuptake inhibitors (SSRIs), and tricyclic drugs, principally. The therapeutic effect of serotonergic drugs as the SSRIs, starting with the binding to auto-receptors, which produces increases of 5-HT in the synaptic cleft as consequence of blockade of serotonin reuptake. While these molecular events occur initially, in the long-term are produced plastic changes at neuronal level, as well as down-regulation of the 5-HT 1A -R, which is associated with the therapeutic effects of antidepressant drugs. The purpose of this chapter is to analyze and discuss the current information about of 5-HT 1A -R-mediated signaling cascades, the intracellular signaling of 5-HT 1A -R, in addition to their expression and pharmacology that are important to treatment of affective disorders symptoms.

show abstract

Section: Serotonin -A Chemical Messenger Between All Types Of Living mentioning

confidence: 91%

Section: Serotonin -A Chemical Messenger Between All Types Of Living mentioning

confidence: 99%

Association of 5-HT1A Receptors with Affective Disorders

Soria-Fregozo¹,

Vega²,

FranciscoRodríguez-Landa³

et al. 2017

Serotonin - A Chemical Messenger Between All Types of Living Cells

View full text Add to dashboard Cite

show abstract

“…A post-hoc analysis of two phase III RCTs involving patient with MDD suggested vilazodone could be beneficial in treatment of MDD with anxious features (36). Following 8 weeks of treatment, patients in the active arm showed significant improvement in somatic and psychic symptoms of anxiety compared to placebo.…”

Section: Competitive Environmentmentioning

confidence: 99%

“…Some data suggest a lower sexual dysfunction with vilazodone compared to SSRIs. However, more studies needed to be done to clarify this (36, 37). Overall, more studies are required in order to fully evaluate the potential of vilazodone for patients with anxiety disorders.…”

Section: Competitive Environmentmentioning

confidence: 99%

Emerging drugs for the treatment of anxiety

Murrough

Yaqubi

Sayed

et al. 2015

Expert Opinion on Emerging Drugs

123

View full text Add to dashboard Cite

Introduction Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States and worldwide. Basic research has provided critical insights into the mechanism regulating fear behavior in animals and a host of animal models have been developed in order to screen compounds for anxiolytic properties. Despite this progress, no mechanistically novel agents for the treatment of anxiety have come to market in more than two decades. Areas covered The current review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development. Anxiety and related disorders considered herein include panic disorder, social anxiety disorder, generalized anxiety disorder and posttraumatic stress disorder. The glutamate, neuropeptide and endocannabinoid systems show particular promise as future targets for novel drug development. Expert opinion In the face of an ever-growing understanding of fear related behavior, the field awaits the translation of this research into mechanistically novel treatments. Obstacles will be overcome through close collaboration between basic and clinical researchers with the goal of aligning valid endophenotypes of human anxiety disorders with improved animal models. Novel approaches are needed to move basic discoveries into new, more effective treatments for our patients.

show abstract

“…A potential anxiolytic effect for vilazodone was supported by post hoc analysis of pooled data 10 from patients with anxious depression in 2 MDD studies. In this analysis, a statistically significant difference in Hamilton Anxiety Rating Scale (HARS) 11 total score change from baseline to week 8 was seen in favor of vilazodone 40 mg/d versus placebo (P < .001).…”

mentioning

confidence: 99%

Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder

Durgam¹,

Gommoll²,

Forero³

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and 5-HT 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. Methods: This was a randomized, placebo-controlled, parallel-group, multicenter, flexible-dose study conducted from May 2013-March 2014. Adult patients (18-70 years, inclusive) who met DSM-IV-TR criteria for GAD were randomized (1:1) to placebo or vilazodone 20-40 mg/d for 8 weeks of double-blind treatment. Primary and secondary efficacy parameters were change from baseline to week 8 in the Hamilton Anxiety Rating Scale (HARS) total score and in the Sheehan Disability Scale (SDS) total score, respectively, analyzed using a mixed-effects model for repeated measures approach on a modified intent-to-treat population. Safety outcomes were summarized descriptively. Results: Efficacy analyses were based on 400 patients (placebo = 200, vilazodone = 200); 76% completed the study (placebo = 81%, vilazodone = 71%). The least squares mean difference (95% CI) in total score change from baseline to week 8 was statistically significant for vilazodone versus placebo on the HARS (−2.20 [−3.72 to −0.68]; P = .0048) and on the SDS (−1.89 [−3.52 to −0.26]; P = .0236). Treatment-emergent adverse events reported in ≥ 5% of vilazodone patients and at least twice the rate of placebo were nausea, diarrhea, dizziness, fatigue, delayed ejaculation, and erectile dysfunction. Conclusion: Statistically significant differences in favor of vilazodone 20-40 mg/d versus placebo were seen on all measures of anxiety and functional impairment in patients with GAD. Vilazodone was generally well tolerated, and no new safety concerns were noted. A lthough worrying is a ubiquitous human experience, the worries that characterize generalized anxiety disorder (GAD) are so pervasive and excessive that they distort cognition and create a considerable burden of illness. The physical symptoms, psychiatric symptoms, and functional impairment associated with GAD collectively generate significant individual, societal, and economic costs.1 As such, GAD is an important mental health issue that affects patients, families, health care providers, payers, employers, and society at large. 1,2 Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and 5-HT 1A receptor partial agonist that is approved by the US Food and Drug Administration (FDA) for treating major depressive disorder (MDD) in adults. SSRIs are first-line agents approved for treating GAD 3 ; unlike other SSRIs, vilazodone also is a 5-HT 1A receptor partial agonist. Based on clinical-trial evidence in MDD, 4-7 the recommended daily dose of vilazodone is 20-40 mg.8 Since SSRI antidepressants used for the treatment of GAD have efficacy at the same dose levels that are effective in treating MDD, 9 vilazodone 20-40 mg/d is being evaluated for GAD treatment.A potential anxiolytic effect for vilazodone wa...

show abstract

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder

Cited by 41 publications

References 26 publications

Association of 5-HT1A Receptors with Affective Disorders

Association of 5-HT1A Receptors with Affective Disorders

Emerging drugs for the treatment of anxiety

Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder

Contact Info

Product

Resources

About